In particular, EpCAM-MC is a personalized APEC-immunotherapy for ovarian cancer that cleaves a CMV peptide (NLVPMVATV; abbreviated NLV) by tumor-expressed MMP7 and then is presented by MHCI (HLA-A*02:01). This evidence concerns the gene EPCAM and ovarian carcinoma.